Real-World Outcomes Associated With Letermovir Use for Cytomegalovirus Primary Prophylaxis in Allogeneic Hematopoietic Cell Transplant Recipients: A Systematic Review and Meta-analysis of Observational Studies
Open Forum Infectious Diseases · 04.01.2023 · 10 (1)
DOI: 10.1093/ofid/ofac687 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Open Forum Infectious Diseases, online erschienen am 22.12.2022. Verfasst von Ami Vyas und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Practice, College of Pharmacy, University of Rhode Island, Kingston, Rhode Island, USA. Die Arbeit wurde bisher 81-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
A systematic review and meta-analysis of real-world observational studies was conducted to summarize the impact of letermovir cytomegalovirus (CMV) primary prophylaxis (PP) among adult allogeneic hematopoietic cell transplant (allo-HCT) recipients.
Methods
Systematic searches in Medline/PubMed, Embase, and conferences (from database inception to October 2021) were conducted to identify studies for inclusion. Random-effects models were used to derive pooled estimates on the relative effectiveness of letermovir PP compared to controls.
Results
Forty-eight unique studies (N = 7104 patients) were included, most of which were comparative, single-center, and conducted in the United States. Letermovir PP was associated with statistically significant reduction in odds of CMV reactivation (pooled odds ratio [pOR], 0.13 and 0.24; P < .05), clinically significant CMV infection (pOR, 0.09 and 0.19; P < .05), and CMV disease (pOR, 0.31 and 0.35; P < .05) by day +100 and day +200 after allo-HCT, respectively. Letermovir PP was associated with significantly lower odds of all-cause (pOR, 0.73; P < .01) and nonrelapse mortality (pOR, 0.65; P = .01) beyond day 200 after allo-HCT.
Conclusions
Letermovir for CMV PP was effective in reducing the risk of CMV-related complications overall and mortality beyond day 200 among adult allo-HCT recipients.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacy Practice, College of Pharmacy, University of Rhode Island, Kingston, Rhode Island, USA.
- Center for Observational and Real-World Evidence, Merck & Co., Inc., Rahway, New Jersey, USA.
- Department of Infectious Diseases, Infection Control, and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Zitieren
APA
Vyas, A., Raval, A. D., Kamat, S., LaPlante, K., Tang, Y., & Chemaly, R. F. (2023). Real-World Outcomes Associated With Letermovir Use for Cytomegalovirus Primary Prophylaxis in Allogeneic Hematopoietic Cell Transplant Recipients: A Systematic Review and Meta-analysis of Observational Studies. Open Forum Infectious Diseases, 10(1). https://doi.org/10.1093/ofid/ofac687
Vancouver
Vyas A, Raval AD, Kamat S, LaPlante K, Tang Y, Chemaly RF. Real-World Outcomes Associated With Letermovir Use for Cytomegalovirus Primary Prophylaxis in Allogeneic Hematopoietic Cell Transplant Recipients: A Systematic Review and Meta-analysis of Observational Studies. Open Forum Infectious Diseases. 2023;10(1). doi:10.1093/ofid/ofac687
BibTeX
@article{Vyas2023,
author = {Vyas, Ami and Raval, Amit D and Kamat, Shweta and LaPlante, Kerry and Tang, Yuexin and Chemaly, Roy F},
title = {Real-World Outcomes Associated With Letermovir Use for Cytomegalovirus Primary Prophylaxis in Allogeneic Hematopoietic Cell Transplant Recipients: A Systematic Review and Meta-analysis of Observational Studies},
journal = {Open Forum Infectious Diseases},
year = {2023},
volume = {10},
number = {1},
doi = {10.1093/ofid/ofac687}
}
EUVIMED